Saturday, October 3, 2026

USD/EUR Bearish Momentum With A 2% Drop In The Last 21 Sessions

ViaNews Editorial Team

August 26, 2024

USD/EUR Bearish Momentum With A 2% Drop In The Last 21 Sessions

(VIANEWS) - USD/EUR (USDEUR) has been up by 2.75% for the last 21 sessions. At 17:15 EST on Monday, 26 August, USD/EUR (USDEUR) is $0.90.

USD/EUR's yearly highs and lows, it's 0.347% up from its 52-week low and 6.416% down from its 52-week high.

Volatility

USD/EUR's last week, last month's, and last quarter's current intraday variation average was a negative 0.33%, a negative 0.18%, and a positive 0.27%, respectively.

USD/EUR's highest amplitude of average volatility was 0.46% (last week), 0.34% (last month), and 0.27% (last quarter), respectively.

Forex Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, USD/EUR's Forex is considered to be overbought (>=80).

News about

  • According to FXStreet on Monday, 26 August, "On the downside, the USD/JPY pair may navigate the region around the seven-month low of 141.69, which was recorded on August 5. ", "In terms of resistance, the USD/JPY pair may test the immediate barrier at the downtrend line around the psychological level of 145.00, followed by the nine-day Exponential Moving Average (EMA) at the 145.74 level. "
  • Usd/jpy extends decline on negative view of US interest rates in the long term. According to FXStreet on Monday, 26 August, "However, given the Japanese Yen (JPY) is now trending higher and most of its favored carry counterparts are weakening, the carry trade is not as profitable as it used to be, and this "unwind" in long held carry positions is further propelling USD/JPY lower."
  • Usd/jpy: more downside – OCBC. According to FXStreet on Monday, 26 August, "Broader direction of travel for USD/JPY has changed as Fed-BoJ policies shifted from divergence to convergence and this should continue to underpin the downside for USD/JPY. "

More news about USD/EUR (USDEUR).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
Apple Inc.
The observation date (2025-12-27) precedes Q1 2026, making it logically impossible to have actual Q1 2026 cash data at that point. Q1 2026 would not end until March 31, 2026. Additionally, the magnitude of the difference ($45.3B vs $132.42) is implausibly large even as a normal quarterly change for Apple. While different fiscal periods can show different values, the timing relationship here suggests a data integrity issue rather than legitimate period-over-period variation.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,329 source documents archived
Query this data → isubstrate.com